NFKB1 and irritable bowel syndrome: Recently, there are evidences for immune activation and low-grade mucosal inflammation, characterized by activating intestinal NF-κB signal pathway and abnormal amounts of immune cells, in the colon and ileum of IBS patients (Juan et al., 2014).